



PRESS RELEASE

For Immediate Release

American Board of Pathology Announces the Appointment of Zahra Maleki, MD, FCAP, MIAC to the Test Development and Advisory Committee for Cytopathology

TAMPA, Fla., Jan. 11, 2023 - The American Board of Pathology (ABPath) is pleased to announce the appointment of **Zahra Maleki, MD, FCAP, MIAC** to the ABPath's Test Development and Advisory Committee (TDAC) for Cytopathology Test Development and Advisory Committee beginning in 2023. The TDACs are responsible for developing and reviewing the ABPath certification exam questions that assess and certify a physician's education, knowledge, experience, and skills in order to provide high-quality care in the pathology profession.

Dr. Zahra Maleki is an Associate Professor of pathology at the Johns Hopkins Hospital, Division of Cytopathology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. She is also the Director of Histology and Pathobiology at the Johns Hopkins Medical School.

She completed Pathology residency in Anatomic Pathology and Clinical Pathology at the Virginia Commonwealth University School of Medicine, followed by her first fellowship in surgical pathology at the Virginia Commonwealth University School of Medicine in Richmond, Virginia. She completed her second fellowship in Cytopathology at the University of Miami School of Medicine in Miami, Florida. She is board certified in Anatomical Pathology, Clinical Pathology and Cytopathology.

Dr. Maleki is the co-author of several cytopathology books including the Milan System for Reporting Salivary Gland Cytopathology and the Paris System for Reporting Urinary Cytology. She has published over 100 peer-reviewed original research and review articles, covering a broad spectrum of cytopathology. Dr. Maleki's areas of research interests include head and neck cytopathology including high-risk human papilloma virus (HPV) related head and neck carcinomas, salivary gland cytopathology, lung neoplasms, and ancillary studies. Her focus is on integrating cytomorphologic features, immunoprofile and molecular aspects of the head and neck and lung neoplasms to improve patient care by optimizing diagnosis and prognosis of the related neoplasms.

Dr. Maleki is a nationally and internationally well-recognized speaker in the field of cytology with numerous presentations at the ASC, USCAP, ASCP, and ICC. She has a passion for cytology and has devoted her time and expertise to serving pathology societies and organizations including ASC, USCAP, and CAP. She served as former chair of Membership Committee at the American Society of Cytopathology.

Dr. Maleki created her own cytology tweeter, called #CytoPro, as an educational cytology source during COVID-19 pandemic lockdown.

Dr. Maleki serves in editorial board of several Pathology journals including *Cancer Cytopathology*, *Journal of the American Society of Cytopathology*, *American Journal of Clinical Pathology*, *Acta Cytologica*, *Diagnostic Cytopathology* and *Cytopathology*.

To be appointed to a TDAC means a physician is an established subject matter expert in their subspecialty field and is current on the latest advances in the continually evolving field of pathology and patient care. TDAC committee members develop and review examination questions for statistical performance and relevance to current practice. They contribute to the validity of examinations by determining the content and distribution of items on examinations (exam blueprints). The TDACs also advise the ABPath on issues in their subspecialty area of expertise.

“The members of our Test Development and Advisory committees are experts in their respective fields. These individuals are instrumental in assessment development, the setting of standards, and provide guidance regarding the current state of Pathology. The appointment of an individual to a test committee is a recognition of their expertise and their contributions ensures the integrity and relevance of board certification,” states Gary W. Procop, MD, CEO of the American Board of Pathology.

Since 1971, the ABPath has appointed test committees for each specialty area of pathology. The committee consists of ABPath trustees and other pathologists or specialty physicians who are recognized experts in their respective disciplines. There are presently 14 ABPath TDACs. They are: Anatomic Pathology, Anatomic Pathology CertLink®, Blood Banking/Transfusion Medicine, Chemical Pathology, Clinical Pathology CertLink®, Management and Informatics, Cytopathology, Dermatopathology (with appointees from the American Board of Dermatology), Forensic Pathology, Hematopathology, Medical Microbiology, Molecular Genetic Pathology (with appointees from the American Board of Medical Genetics and Genomics), Neuropathology, and Pediatric Pathology.

About the American Board of Pathology

The mission of the American Board of Pathology, as a member of the American Board of Medical Specialties, is to serve the public and advance the profession of pathology by setting certification standards and promoting lifelong competency of pathologists. Founded in 1936, the ABPath accomplishes this mission by establishing certification and continuing certification standards and assessing the qualifications of those seeking to obtain voluntary certification in the specialty of pathology. For more information on ABPath, visit abpath.org or call (813) 286-2444.

###

Contact:

Bonnie A. Woodworth
Communications Director
American Board of Pathology
(813) 724-3707
bwoodworth@abpath.org
abpath.org